Antibody | Time | Treatment | ||
---|---|---|---|---|
Saline | LY379268 (10 mg/kg i.p.) | BCAO (Positive Control) | ||
h | ||||
BDNF | 6 | − | − | − |
24 | − | − | − | |
72 | − | − | + | |
120 | − | − | +++ | |
NGF | 6 | − | − | − |
24 | − | − | − | |
72 | − | − | + | |
120 | − | − | ++++ | |
bFGF | 6 | − | − | − |
24 | − | − | − | |
72 | − | − | ++ | |
120 | − | − | + | |
TGF-β1 | 6 | − | − | − |
24 | − | − | − | |
72 | − | − | +++ | |
120 | − | − | +++ | |
TGF-β2 | 6 | − | − | − |
24 | − | − | − | |
72 | − | − | +++ | |
120 | − | − | +++ |
The effect of LY379268 on immunohistochemical staining for these neurotrophic factors was examined by light microscopy in the CA1 area of the hippocampus of 6-μm sections using 5-min BCAO as a positive control. Immunostaining product is described on a quantitative scale of −, no staining; +, little staining; ++, moderate staining; +++, intense staining; and ++++, most intense staining.